Compare Dr. Reddys with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PROCTER & GAMBLE HEALTH - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PROCTER & GAMBLE HEALTH DR. REDDYS LAB/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 34.3 17.9 191.6% View Chart
P/BV x 4.7 7.2 65.1% View Chart
Dividend Yield % 0.6 6.6 8.6%  

Financials

 DR. REDDYS LAB   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
PROCTER & GAMBLE HEALTH
Dec-18
DR. REDDYS LAB/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3,3633,549 94.8%   
Low Rs2,3521,301 180.7%   
Sales per share (Unadj.) Rs1,054.2511.4 206.1%  
Earnings per share (Unadj.) Rs121.961.3 198.9%  
Cash flow per share (Unadj.) Rs190.274.0 257.0%  
Dividends per share (Unadj.) Rs25.00440.00 5.7%  
Dividend yield (eoy) %0.918.1 4.8%  
Book value per share (Unadj.) Rs938.7927.8 101.2%  
Shares outstanding (eoy) m166.1716.60 1,001.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.7 57.2%   
Avg P/E ratio x23.439.6 59.2%  
P/CF ratio (eoy) x15.032.8 45.8%  
Price / Book Value ratio x3.02.6 116.5%  
Dividend payout %20.5717.9 2.9%   
Avg Mkt Cap Rs m474,83140,257 1,179.5%   
No. of employees `00021.71.1 1,909.2%   
Total wages/salary Rs m33,8021,313 2,575.0%   
Avg. sales/employee Rs Th8,091.07,486.7 108.1%   
Avg. wages/employee Rs Th1,561.31,157.6 134.9%   
Avg. net profit/employee Rs Th935.8897.2 104.3%   
INCOME DATA
Net Sales Rs m175,1708,490 2,063.3%  
Other income Rs m6,206244 2,544.5%   
Total revenues Rs m181,3768,734 2,076.7%   
Gross profit Rs m24,4211,482 1,648.3%  
Depreciation Rs m11,348211 5,373.1%   
Interest Rs m9830-   
Profit before tax Rs m18,2961,514 1,208.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m-1,403563 -249.4%   
Profit after tax Rs m20,2601,017 1,991.4%  
Gross profit margin %13.917.5 79.9%  
Effective tax rate %-7.737.1 -20.6%   
Net profit margin %11.612.0 96.5%  
BALANCE SHEET DATA
Current assets Rs m125,99115,343 821.2%   
Current liabilities Rs m72,1411,960 3,680.3%   
Net working cap to sales %30.7157.6 19.5%  
Current ratio x1.77.8 22.3%  
Inventory Days Days7349 149.9%  
Debtors Days Days10528 368.3%  
Net fixed assets Rs m83,8541,209 6,934.1%   
Share capital Rs m831166 500.6%   
"Free" reserves Rs m155,15715,235 1,018.4%   
Net worth Rs m155,98815,401 1,012.8%   
Long term debt Rs m1,3040-   
Total assets Rs m232,25317,595 1,320.0%  
Interest coverage x19.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 156.3%   
Return on assets %9.15.8 158.2%  
Return on equity %13.06.6 196.6%  
Return on capital %12.610.3 123.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,1931,636 5,145.3%   
Fx outflow Rs m39,6164,368 906.9%   
Net fx Rs m44,577-2,732 -1,631.8%   
CASH FLOW
From Operations Rs m29,841-1,304 -2,288.8%  
From Investments Rs m-4,92312,697 -38.8%  
From Financial Activity Rs m-25,159-301 8,372.4%  
Net Cashflow Rs m-26611,093 -2.4%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 5.4 18.2 29.7%  
FIIs % 35.3 1.0 3,530.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 29.1 52.6%  
Shareholders   75,885 28,591 265.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 26, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - DISHMAN PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS